ArticleMolecular biotechnology2021
Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19.
Article in Molecular biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Novel bioinformatics approaches to design epitope-based vaccine against HIV latency by inquiring CTL epitopes and built-in adjuvants.Scientific reports · 2025Article
- Designing a multi-epitope universal vaccine for concurrent infections of SARS-CoV-2 and influenza viruses using an immunoinformatics approach.BMC infectious diseases · 2025Article
- Computational design and evaluation of multiepitope vaccines against herpes simplex virus type 1.Frontiers in immunology · 2025Article
- A plant secretory sequence enhances immunogenicity of electroporated COVID-19 DNA vaccines.Frontiers in medical technology · 2025Article
- Lessons from COVID-19 Pandemic: A Successful Policy and Practice by Pasteur Institute of Iran.Iranian biomedical journal · 2024Article
- Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine.Heliyon · 2023Article
- Mapping Potential Vaccine Candidates Predicted by VaxiJen for Different Viral Pathogens between 2017-2021-A Scoping Review.Vaccines · 2022Article
- Preliminary study on designing the binder of sperm-1 synthetic vaccine using sequence-based methods and molecular docking.Journal of advanced veterinary and animal research · 2022Article
- SARS-CoV-2 Viral Shedding and Associated Factors among COVID-19 Inpatients and Outpatients.Interdisciplinary perspectives on infectious diseases · 2022Article
- Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.BioMed research international · 2022Article
- EpiBuilder: A Tool for Assembling, Searching, and Classifying B-Cell Epitopes.Bioinformatics and biology insights · 2022Article
- Investigation of nonsynonymous mutations in the spike protein of SARS-CoV-2 and its interaction with the ACE2 receptor by molecular docking and MM/GBSA approach.Computers in biology and medicine · 2021Article
- SARS-CoV-2 presented moderately during two episodes of the infection with lack of antibody responses.Virus research · 2021Article
- Development of an indirect ELISA to specifically detect antibodies against African swine fever virus: bioinformatics approaches.Virology journal · 2021Article
- Prolonged viral shedding and antibody persistence in patients with COVID-19.Microbes and infectionArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The emerging Coronavirus Disease 2019 (COVID-19) pandemic has posed a serious threat to the public health worldwide, demanding urgent vaccine provide. According to the virus feature as an RNA virus, a high rate of mutations imposes some vaccine design difficulties. Bioinformatics tools have been widely used to make advantage of conserved regions as well as immunogenicity. In this study, we aimed at immunoinformatic evaluation of SARS-CoV-2 proteins conservancy and immunogenicity to design a preventive vaccine candidate. Spike, Membrane and Nucleocapsid amino acid sequences were obtained, and four possible fusion proteins were assessed and compared in terms of structural features and immunogenicity, and population coverage. MHC-I and MHC-II T-cell epitopes, the linear and conformational B-cell epitopes were evaluated. Among the predicted models, the truncated form of Spike in fusion with M and N protein applying AAY linker has high rate of MHC-I and MCH-II epitopes with high antigenicity and acceptable population coverage of 82.95% in Iran and 92.51% in Europe. The in silico study provided truncated Spike-M-N SARS-CoV-2 as a potential preventive vaccine candidate for further in vivo evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.